Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opportunities to Optimize Cancer Policies Panel Discussion

Welcome and Introduction to Vi3C

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Aug
12
Today In Oncology
Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care
AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
NIH-Funded International Research Yields Patient-Derived Tumor Compendium
Stanford Appoints New Leader to Expand Impact in Early Drug Development
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo